Détail du document
Identifiant

doi:10.1186/s12864-023-09301-9...

Auteur
Gu, Langyu Xia, Canwei Yang, Shiyu Yang, Guofen
Langue
en
Editeur

BioMed Central

Catégorie

Life Sciences

Année

2023

Date de référencement

26/04/2023

Mots clés
cancer driver genes positive selection primates modern human populations thyroid cancer types humans analysis thyroid genes evolution populations human selection
Métrique

Résumé

Background Cancer is a life-threatening disease in humans; yet, cancer genes are frequently reported to be under positive selection.

This suggests an evolutionary-genetic paradox in which cancer evolves as a secondary product of selection in human beings.

However, systematic investigation of the evolution of cancer driver genes is sparse.

Results Using comparative genomics analysis, population genetics analysis and computational molecular evolutionary analysis, the evolution of 568 cancer driver genes of 66 cancer types were evaluated at two levels, selection on the early evolution of humans (long timescale selection in the human lineage during primate evolution, i.e., millions of years), and recent selection in modern human populations (~ 100,000 years).

Results showed that eight cancer genes covering 11 cancer types were under positive selection in the human lineage (long timescale selection).

And 35 cancer genes covering 47 cancer types were under positive selection in modern human populations (recent selection).

Moreover, SNPs associated with thyroid cancer in three thyroid cancer driver genes (CUX1, HERC2 and RGPD3) were under positive selection in East Asian and European populations, consistent with the high incidence of thyroid cancer in these populations.

Conclusions These findings suggest that cancer can be evolved, in part, as a by-product of adaptive changes in humans.

Different SNPs at the same locus can be under different selection pressures in different populations, and thus should be under consideration during precision medicine, especially for targeted medicine in specific populations.

Gu, Langyu,Xia, Canwei,Yang, Shiyu,Yang, Guofen, 2023, The adaptive evolution of cancer driver genes, BioMed Central

Document

Ouvrir

Partager

Source

Articles recommandés par ES/IODE IA

MELAS: Phenotype Classification into Classic-versus-Atypical Presentations
presentations mitochondrial strokelike patients variability phenotype clinical melas
Protocol for the promoting resilience in stress management (PRISM) intervention: a multi-site randomized controlled trial for adolescents and young adults with advanced cancer
cancer quality of life anxiety depression hope coping skills communication intervention randomized ayas outcomes resilience care trial cancer prism-ac advanced